LENZ vs AEYE vs ALKT vs PRPH

For growth investors, Alkami Technology, Inc.

(ALKT) is the stronger pick with 32. 9% revenue growth year-over-year, versus -84. 7% for ProPhase Labs, Inc. (PRPH). Analysts rate LENZ Therapeutics, Inc. (LENZ) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Alkami Technology, Inc.

(ALKT) delivered a total return of -54. 9%, compared to -72. 4% for LENZ Therapeutics, Inc. (LENZ). Over 10 years, the gap is even starker: AEYE returned +102. 2% versus LENZ's -72. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Alkami Technology, Inc.

(ALKT) is the lower-risk stock at 1. 30β versus AudioEye, Inc. 's 2. 29β — meaning AEYE is approximately 76% more volatile than ALKT relative to the S&P 500. On balance sheet safety, LENZ Therapeutics, Inc. (LENZ) carries a lower debt/equity ratio of 0% versus 3% for ProPhase Labs, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Alkami Technology, Inc.

(ALKT) is pulling ahead at 32. 9% versus -84. 7% for ProPhase Labs, Inc. (PRPH). On earnings-per-share growth, the picture is similar: AudioEye, Inc. grew EPS 30. 6% year-over-year, compared to -166. 3% for ProPhase Labs, Inc.. Over a 3-year CAGR, ALKT leads at 29. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

AudioEye, Inc.

(AEYE) is the more profitable company, earning -7. 6% net margin versus -788. 2% for ProPhase Labs, Inc. — meaning it keeps -7. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AEYE leads at -7. 9% versus -570. 6% for PRPH. At the gross margin level — before operating expenses — LENZ leads at 97. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for LENZ: 431.

6% to $51. 67.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Alkami Technology, Inc.

(ALKT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. ProPhase Labs, Inc. (PRPH) carries a higher beta of 2. 28 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ALKT: -59. 5%, PRPH: +37. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (LENZ (Healthcare) and AEYE (Technology) and ALKT (Technology) and PRPH (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: LENZ is a small-cap quality compounder stock; AEYE is a small-cap quality compounder stock; ALKT is a small-cap high-growth stock; PRPH is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.